Petrelintide
Petrelintide is a peptide, indexed here under Amylin and amylin receptor agonists.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Amylin and amylin receptor agonists |
| CAS registry number | Unknown No CAS-format synonym was present on the retrieved PubChem record. |
| PubChem CID | 172915807[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C185H305N49O61[1] |
| Molecular weight | 4192 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Petrelintide, development code ZP8396, is described in a 2025 Journal of Medicinal Chemistry paper as a potent, stable, long-acting human amylin analogue. Its retrieved literature is small and recent.
A 2026 Diabetes, Obesity and Metabolism paper reports safety, tolerability, pharmacokinetics and pharmacodynamics for weight management in two randomised controlled studies, a 2026 Lancet Diabetes and Endocrinology paper reports the randomised double-blind placebo-controlled ZUPREME 1 trial in obesity, and an accompanying 2026 comment in the same journal discusses the evolving role of amylin agonism.
[3, 4, 5, 6]Reported mechanism
A long-acting human amylin analogue, per the retrieved records.
[3]Stated in the title of the cited 2025 Journal of Medicinal Chemistry paper.
Targets named in the cited records: amylin receptors.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Petrelintide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- ZP8396
Where this page sits
Research records
Cited research records for Petrelintide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Cagrilintide — Amylin and amylin receptor agonists
- Eloralintide — Amylin and amylin receptor agonists
Class page: Amylin and amylin receptor agonists. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Petrelintide?
Petrelintide, development code ZP8396, is described in a 2025 Journal of Medicinal Chemistry paper as a potent, stable, long-acting human amylin analogue. Its retrieved literature is small and recent.
Which class is Petrelintide indexed under?
Petrelintide is indexed under Amylin and amylin receptor agonists. This class groups the pancreatic hormone amylin, also called islet amyloid polypeptide, and the synthetic analogues modelled on it.
What does the FDA application register show for Petrelintide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 172915807, Petrelintide. PubChem, National Library of Medicine (2026). pubchem:172915807
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:petrelintide
- Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. Journal of medicinal chemistry (2025). pmid:41217931
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes, obesity & metabolism (2026). pmid:42017294
- Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. The lancet. Diabetes & endocrinology (2026). pmid:42810355
- Petrelintide and the evolving role of amylin agonism in obesity. The lancet. Diabetes & endocrinology (2026). pmid:42810353
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.